Utility of a Novel Micro-Spraying Device for Intranasal Administration of Drug Solutions to Mice.

intranasal administration inulin mice micro-spraying device nose-to-brain

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
29 Oct 2023
Historique:
received: 01 10 2023
revised: 23 10 2023
accepted: 26 10 2023
medline: 25 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Intranasal administration has attracted attention as a means of delivering drugs because it bypasses the blood-brain barrier. However, conventional intranasal administration of drug solutions to mice using the micropipette method (MP method) is complicated and time-consuming because it requires small doses to be administered under inhalation anesthesia. This study evaluated the effectiveness of a novel intranasal administration method using Micro FPS™, a novel micro-spraying device (the MSD method). The MSD method allowed more reliable administration of the solution to the nasal mucosa than the MP method did. The transfer of inulin, a model water-soluble macromolecule compound, to the olfactory bulb and brain (cerebrum, cerebellum, brainstem, and striatum) was similar with the two methods. It also allowed the drug to be administered in a shorter time. These results suggest that the MSD method is simpler and more rapid than the MP method for intranasal administration of drugs to mice and achieves comparable delivery of inulin to the olfactory bulb and brain. Therefore, the Micro FPS™ device is a potentially useful tool for intranasal drug administration to rodents and could facilitate the development of intranasal formulations, contributing to drug development for central nervous system diseases.

Identifiants

pubmed: 38004533
pii: pharmaceutics15112553
doi: 10.3390/pharmaceutics15112553
pmc: PMC10675388
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : JSPS KAKENHI, a Grant-in-Aid for Early-Career Scientists
ID : 20K16059
Organisme : JSPS KAKENHI, a Grant-in-Aid for Early-Career Scientists
ID : 23K14395
Organisme : OTC Self-Medication Promotion Foundation
ID : 9-1-9
Organisme : Nihon University Multidisciplinary Research Grant
ID : 2019-2020
Organisme : Nihon University Multidisciplinary Research Grant
ID : 2022-2023

Références

Adv Drug Deliv Rev. 2021 Mar;170:340-352
pubmed: 32918968
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S5
pubmed: 19091002
J Control Release. 2021 Apr 10;332:493-501
pubmed: 33647429
Mol Pharm. 2016 Mar 7;13(3):1004-11
pubmed: 26795701
Pharmaceutics. 2021 Nov 30;13(12):
pubmed: 34959331
Pharm Res. 2019 Apr 1;36(5):76
pubmed: 30937626
Eur J Clin Pharmacol. 2003 Nov;59(8-9):631-6
pubmed: 14564429
Diabetes Ther. 2020 Jul;11(7):1591-1603
pubmed: 32514794
Curr Probl Dermatol. 2011;40:20-35
pubmed: 21325837
J Pharm Sci. 2010 Apr;99(4):1654-73
pubmed: 19877171
Mol Pharm. 2014 Apr 7;11(4):1081-93
pubmed: 24601686
Eur Arch Otorhinolaryngol. 2006 Sep;263(9):827-32
pubmed: 16807754
Eur J Pharm Sci. 2022 Nov 1;178:106290
pubmed: 36058500
J Control Release. 2015 Jan 10;197:105-10
pubmed: 25445695
J Drug Target. 1998;5(6):415-41
pubmed: 9783675
Eur J Pharm Sci. 2000 Jul;11(1):1-18
pubmed: 10913748
Drug Discov Today. 2022 Aug;27(8):2300-2308
pubmed: 35452791
Sci Rep. 2016 Aug 25;6:31732
pubmed: 27558973
Neuroscience. 2004;127(2):481-96
pubmed: 15262337
J Pharm Sci. 1987 Jul;76(7):535-40
pubmed: 2889824
J Vis Exp. 2013 Apr 08;(74):
pubmed: 23608783
Neuroscience. 2008 Mar 27;152(3):785-97
pubmed: 18304744
Front Pharmacol. 2022 Jan 10;12:789780
pubmed: 35082672
AAPS J. 2015 May;17(3):493-505
pubmed: 25693488
J Control Release. 2022 Apr;344:225-234
pubmed: 35296406
J Vis Exp. 2018 Nov 14;(141):
pubmed: 30507914
J Neurosci Methods. 2017 Jul 15;286:16-21
pubmed: 28499841
Int J Nanomedicine. 2014 May 10;9:2241-57
pubmed: 24872687
Pharm Res. 2013 Oct;30(10):2475-84
pubmed: 23135822
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Biomaterials. 2013 Dec;34(36):9220-6
pubmed: 23992922
Pharmaceutics. 2022 Nov 24;14(12):
pubmed: 36559085
J Vis Exp. 2019 Aug 15;(150):
pubmed: 31475960
Drug Dev Ind Pharm. 2020 Jan;46(1):8-19
pubmed: 31809608

Auteurs

Naoto Suzuki (N)

Laboratory of Pharmaceutics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Hiroaki Tanigawa (H)

Laboratory of Pharmaceutics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Taiki Nagatomo (T)

Laboratory of Pharmaceutics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Hiroko Miyagishi (H)

Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Takanori Kanazawa (T)

Department of Clinical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, 1-78-1 Shoumachi, Tokushima 770-8505, Tokushima, Japan.

Toyofumi Suzuki (T)

Laboratory of Pharmaceutics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Yasuhiro Kosuge (Y)

Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Chiba, Japan.

Classifications MeSH